Celon Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Celon Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $2.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Celon Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $2.3M Trade | TransData Nexus

Celon Laboratories Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $2.3M Total Trade · DGFT Verified

Celon Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.3M across 13 products in 3 therapeutic categories. Based on 262 verified export shipments from Indian Customs (DGFT) records, Celon Laboratories Private Limited is the #1 Indian exporter in 1 product including Chlorambucil. Top exports include Carboplatin ($628.5K), Oxaliplatin ($558.4K), Cytarabine ($313.6K).

Celon Laboratories Private Limited — Export Portfolio & Destination Treemap

Celon Laboratories Private Limited pharmaceutical export portfolio — 13 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Celon Laboratories Private Limited? — Company Overview & Market Position

Celon Laboratories Private Limited, established on January 23, 2001, is a specialty-focused biopharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the development, manufacturing, and marketing of high-quality formulations in niche therapeutic areas, particularly oncology and critical care. Celon operates under the Corporate Identification Number (CIN) U24232TG2001PTC036097. As of November 15, 2024, the company employed approximately 535 individuals. Celon Laboratories is privately held, with a promoter holding of 92.83% as of FY 2024. The company's official website is www.celonlabs.com.

What Does Celon Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Carboplatin$628.5K 2Oxaliplatin$558.4K

Product Portfolio — Top 13 by Export Value

Celon Laboratories Private Limited exports 13 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Carboplatin	Oncology	$628.5K	45	0.9%	14
2	Oxaliplatin	Advanced Oncology	$558.4K	46	1.2%	14
3	Cytarabine	Advanced Oncology	$313.6K	44	2.9%	5
4	Bleomycin	Advanced Oncology	$140.4K	18	2.5%	9
5	Exemestane	Advanced Oncology	$119.7K	10	0.8%	11
6	Epirubicin	Advanced Oncology	$89.7K	8	1.4%	10
7	Chlorambucil	Advanced Oncology	$87.5K	18	25.5%	1
8	Teicoplanin	Advanced Antibiotics	$82.4K	6	1.3%	9
9	Actinomycin	Advanced Oncology	$67.3K	16	2.3%	4
10	Dacarbazine	Advanced Oncology	$52.8K	16	3.7%	7
11	Melphalan	Advanced Oncology	$51.7K	11	0.4%	10
12	Vincristine	Oncology	$39.4K	21	1.9%	12
13	Ifosfamide	Advanced Oncology	$31.7K	3	1.3%	12

Celon Laboratories Private Limited exports 13 pharmaceutical products across 3 therapeutic categories with a total export value of $2.3M. The company is the #1 Indian exporter in 1 product: Chlorambucil. The top category is Advanced Oncology (66.8% of portfolio), followed by Oncology (29.5%), indicating a concentrated portfolio with the top 5 products accounting for 77.8% of total export value.

Celon Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Celon Laboratories operates multiple manufacturing facilities in Hyderabad, Telangana, India. These facilities are equipped to produce a comprehensive range of pharmaceutical formulations, including uncoated and coated tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. The company emphasizes adherence to global quality standards, ensuring that its manufacturing processes comply with current Good Manufacturing Practices (cGMP) and International Council for Harmonisation (ICH) guidelines.

3Key Leadership

The leadership team at Celon Laboratories includes:

Vivek Kaushik: Chief Executive Officer (CEO)

K. V. Ravindra: Founder and Managing Director

These executives play pivotal roles in steering the company's strategic direction and operations. (craft.co)

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Celon Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Celon Laboratories has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has secured approvals for its products from various global regulatory authorities, including INVIMA (Colombia), NAFDAC (Nigeria), and DRAP (Pakistan). These approvals facilitate the company's market access and distribution in these regions.

2Emerging Markets

Celon Laboratories has expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are registered with regulatory bodies such as INVIMA (Colombia), NAFDAC (Nigeria), and DRAP (Pakistan), enabling access to these markets. Additionally, Celon has partnered with organizations like the Akshaya Patra Foundation to enhance healthcare access in underserved regions.

3Geographic Strategy

Celon Laboratories demonstrates a diversified geographic strategy by establishing a presence in both regulated and emerging markets. This approach mitigates concentration risk and aligns with the company's mission to make high-quality medications accessible globally. The strategic direction focuses on expanding market reach while maintaining compliance with international regulatory standards.

Celon Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Celon Laboratories has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), indicating compliance with FDA standards. The company has also filed Abbreviated New Drug Applications (ANDAs) for its products, seeking approval for marketing in the U.S. market. While specific details on FDA inspections and Drug Master File (DMF) filings are not publicly disclosed, the company's adherence to global quality standards suggests a commitment to meeting FDA requirements.

2WHO & EU GMP

Celon Laboratories' manufacturing facilities are certified by the World Health Organization (WHO) and hold European Union Good Manufacturing Practice (EU GMP) certificates. These certifications affirm the company's commitment to maintaining high-quality manufacturing processes that meet international standards.

3CDSCO & Indian Regulatory

In India, Celon Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company also possesses export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

Celon Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology and critical care pharmaceutical sectors, Celon Laboratories faces competition from both domestic and international companies. While specific market share data is not publicly disclosed, the company's focus on niche therapeutic areas and its comprehensive product portfolio position it as a significant player in these markets. Celon's emphasis on quality, regulatory compliance, and global market access enhances its competitive standing.

2Key Differentiators

Celon Laboratories distinguishes itself through its specialization in oncology and critical care formulations, offering a broad portfolio of injectable pharmaceutical products, including difficult-to-manufacture and urgently needed medical products. The company's in-house research and development capabilities, operational flexibility, and regulatory expertise enable it to bring a wide variety of products from laboratory to market, often on a first-to-market basis post-loss of exclusivity.

3Strategic Position

Celon Laboratories' current strategic direction focuses on expanding its presence in both regulated and emerging markets, with an emphasis on oncology and critical care segments. The company's future outlook includes enhancing its global footprint, leveraging its R&D capabilities to introduce innovative drug delivery systems, and maintaining a commitment to quality and patient-centric solutions.

Buyer Due Diligence Brief — Evaluating Celon Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Celon Laboratories has demonstrated a consistent track record in manufacturing and exporting pharmaceutical formulations, with a total export value of $2.3 million USD across 262 shipments from 2022 to 2026. The company's portfolio includes 13 products across three therapeutic categories, with a concentration in advanced oncology formulations. This consistent export activity and product diversification indicate reliability and a strong presence in international markets.

2Certifications to Verify

Importers should verify the following certifications when considering Celon Laboratories as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure the manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practices.

EU GMP Certification: Verify the European Union Good Manufacturing Practice certification.

Frequently Asked Questions — Celon Laboratories Private Limited

How many pharmaceutical products does Celon Laboratories Private Limited export from India?

Celon Laboratories Private Limited exports 13 pharmaceutical products across 3 therapeutic categories. The top exports are Carboplatin ($628.5K), Oxaliplatin ($558.4K), Cytarabine ($313.6K), Bleomycin ($140.4K), Exemestane ($119.7K). Total export value is $2.3M.

What is Celon Laboratories Private Limited's total pharmaceutical export value?

Celon Laboratories Private Limited's total pharmaceutical export value is $2.3M, based on 262 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Celon Laboratories Private Limited the #1 Indian exporter?

Celon Laboratories Private Limited is the #1 Indian exporter in 1 products: Chlorambucil (25.5% market share).

What therapeutic categories does Celon Laboratories Private Limited cover?

Celon Laboratories Private Limited exports across 3 therapeutic categories. The largest are Advanced Oncology (66.8%, 10 products), Oncology (29.5%, 2 products), Advanced Antibiotics (3.6%, 1 products).

Get Full Celon Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.